Рак молочной железы (РМЖ) в 12% случаев выявляется у женщин в возрасте 20–34 лет. Проблема фертильности и связанных с нею рисков РМЖ сохраняет актуальность для акушеров-гинекологов, онкологов, репродуктологов. Необходимость принятия решения о сохранении беременности при РМЖ, выборе современных методов лечения, улучшении исходов родов для матери и плода требует знаний о современных тенденциях в изучении данной проблемы. В обзоре представлены современные отечественные и зарубежные литературные данные о рисках и возможностях профилактики. Ключевые слова: рак молочной железы, фертильность, беременность, таргетная профилактика рака молочной железы.
________________________________________________
Breast cancer (BC) in 12% diagnosed in women aged 20–34 years. Fertility problems and associated risk of BC is still valid for obstetricians and gynecologists, oncologists, reproductologists. The need for a decision on prolongation of the pregnancy in BC, the choice of modern methods of treatment, improve delivery outcomes for the mother and the fetus requires knowledge of current trends in the study of this problem. In the review the modern Russian and foreign literature data on the risks and opportunities of BC prevention. Key words: breast cancer, fertility, pregnancy, targeted prevention for breast cancer.
1. Асеев А.В., Васютков В.Я., Мурашова З.М. Опыт изучения качества жизни больных раком молочной железы (в условиях областного онкологического диспансера). Маммология. 1995; 3: 40–5. / Aseev A.V., Vasiutkov V.Ia., Murashova Z.M. Opyt izucheniia kachestva zhizni bol'nykh rakom molochnoi zhelezy (v usloviiakh oblastnogo onkologicheskogo dispansera). Mammologiia. 1995; 3: 40–5. [in Russian]
2. Ашрафян Л.А. Спорадический рак яичников: вероятная модель патогенеза. Журн. акушерства и женских болезней. 2012; LXI (Вып. 4): 3–10. / Ashrafian L.A. Sporadicheskii rak iaichnikov: veroiatnaia model' patogeneza. Zhurn. akusherstva i zhenskikh boleznei. 2012; LXI (Vyp. 4): 3–10. [in Russian]
3. Ашрафян Л.А., Киселев В.И. Опухоли репродуктивных органов (этиология и патогенез). М.: Димитрейд График Групп, 2007. / Ashrafian L.A., Kiselev V.I. Opukholi reproduktivnykh organov (etiologiia i patogenez). M.: Dimitreid Grafik Grupp, 2007. [in Russian]
4. Бухарин Д.Г, Слонимская Е.М., Величко С.А. и др. Особенности маммографической визуализации «малых» форм рака молочной железы, развившегося на фоне фиброзно-кистозной болезни. Вопр. онкологии. 2011; 57 (5): 664–7. / Bukharin D.G, Slonimskaia E.M., Velichko S.A. i dr. Osobennosti mammograficheskoi vizualizatsii «malykh» form raka molochnoi zhelezy, razvivshegosia na fone fibrozno-kistoznoi bolezni. Vopr. onkologii. 2011; 57 (5): 664–7. [in Russian]
5. Волочаева М.В., Подушкина Е.С., Шмаков Р.Г., Шетикова О.В. Ведение беременности у женщин с онкологическими заболеваниями (10-летний опыт). Акушерство и гинекология. 2012; 6: 92–8. / Volochaeva M.V., Podushkina E.S., Shmakov R.G., Shetikova O.V. Vedenie beremennosti u zhenshchin s onkologicheskimi zabolevaniiami (10-letnii opyt). Akusherstvo i ginekologiia. 2012; 6: 92–8. [in Russian]
6. Волочаева М.В., Шмаков Р.Г., Зубков В.В. Здоровье детей, рожденных женщинами с раком молочной железы, связанным с беременностью. Акушерство и гинекология. 2014; 7: 33–7. / Volochaeva M.V., Shmakov R.G., Zubkov V.V. Zdorov'e detei, rozhdennykh zhenshchinami s rakom molochnoi zhelezy, sviazannym s beremennost'iu. Akusherstvo i ginekologiia. 2014; 7: 33–7. [in Russian]
7. Головко Т.С., Скляр С.Ю., Крахмалева А.С. и др. Особенности лучевой диагностики редких заболеваний грудной железы опухолевой природы. Клин. онкология. 2011; 3 (3): 86–91. / Golovko T.S., Skliar S.Iu., Krakhmaleva A.S. i dr. Osobennosti luchevoi diagnostiki redkikh zabolevanii grudnoi zhelezy opukholevoi prirody. Klin. onkologiia. 2011; 3 (3): 86–91. [in Russian]
8. Захарова Т. Мастопатия в практике врача первичного звена. Мед. газета. 2014; 13: 8–9. / Zakharova T. Mastopatiia v praktike vracha pervichnogo zvena. Med. gazeta. 2014; 13: 8–9. [in Russian]
9. Иванова О.А. и др. Рак молочной железы и беременность: особенности диагностики и лечения. Злокачественные опухоли. 2014; 1: 14–8. / Ivanova O.A. i dr. Rak molochnoi zhelezy i beremennost': osobennosti diagnostiki i lecheniia. Zlokachestvennye opukholi. 2014; 1: 14–8. [in Russian]
10. Киселев В.И., Сметник В.П, Сутурина Л.В. и др. Индолкарбинол (Индинол Форто) – метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология. 2013; 7. / Kiselev V.I., Smetnik V.P, Suturina L.V. i dr. Indolkarbinol (Indinol Forto) – metod mul'titargetnoi terapii pri tsiklicheskoi mastodinii. Akusherstvo i ginekologiia. 2013; 7. [in Russian]
11. Кит О.И., Франциянц Е.М., Бандовкина В.А. и др. Уровень половых гормонов и пролактина в ткани злокачественных опухолей молочной железы у больных разного возраста. Фундаментальные исследования. 2013; 7: 560–4. / Kit O.I., Frantsiiants E.M., Bandovkina V.A. i dr. Uroven' polovykh gormonov i prolaktina v tkani zlokachestvennykh opukholei molochnoi zhelezy u bol'nykh raznogo vozrasta. Fundamental'nye issledovaniia. 2013; 7: 560–4. [in Russian]
12. Корженкова Г.П. Совершенствование диагностики рака молочной железы в условиях массового маммографического обследования женского населения. Автореф. дис. … д-ра мед. наук. Обнинск, 2013. / Korzhenkova G.P. Sovershenstvovanie diagnostiki raka molochnoi zhelezy v usloviiakh massovogo mammograficheskogo obsledovaniia zhenskogo naseleniia. Avtoref. dis. … d-ra med. nauk. Obninsk, 2013. [in Russian]
13. Моисеенко В.М. «Естественная история» роста рака молочной железы. Практ. онкология. 2002; 3 (1): 6–14. / Moiseenko V.M. «Estestvennaia istoriia» rosta raka molochnoi zhelezy. Prakt. onkologiia. 2002; 3 (1): 6–14. [in Russian]
14. Молочные железы и гинекологические болезни. Под ред. В.Е.Радзинского. М., 2010. / Molochnye zhelezy i ginekologicheskie bolezni. Pod red. V.E.Radzinskogo. M., 2010. [in Russian]
15. Национальное руководство «Акушерство». Под ред. Э.К.Айламазяна, В.И.Кулакова, В.Е.Радзинского, Г.М.Савельевой, 2009. / Natsional'noe rukovodstvo «Akusherstvo». Pod red. E.K.Ailamaziana, V.I.Kulakova, V.E.Radzinskogo, G.M.Savel'evoi, 2009. [in Russian]
16. Нечушкин М.И., Кампова-Полевая Е.Б., Пароконная А.А., Любченко Л.Н. Беременность у женщин, перенесших рак молочной железы. Опухоли женской репродуктивной системы. 2009; 1: 67–71. / Nechushkin M.I., Kampova-Polevaia E.B., Parokonnaia A.A., Liubchenko L.N. Beremennost' u zhenshchin, perenesshikh rak molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2009; 1: 67–71. [in Russian]
17. Основные показатели деятельности акушерско-гинекологической службы в 2012 году. Справочные материалы (под ред. Е.Н.Байбариной). М., 2013. / Osnovnye pokazateli deiatel'nosti akushersko-ginekologicheskoi sluzhby v 2012 godu. Spravochnye materialy (pod red. E.N.Baibarinoi). M., 2013. [in Russian]
18. Пароконная А.А. Рак молочной железы и беременность. Современное состояние проблемы. Практ. онкология. 2009; 10 (4): 179–83. / Parokonnaia A.A. Rak molochnoi zhelezy i beremennost'. Sovremennoe sostoianie problemy. Prakt. onkologiia. 2009; 10 (4): 179–83. [in Russian]
19. Пароконная А.А. Рак молочной железы и беременность. Справ. фельдшера и акушерки. 2010; 1: 53–6. / Parokonnaia A.A. Rak molochnoi zhelezy i beremennost'. Sprav. fel'dshera i akusherki. 2010; 1: 53–6. [in Russian]
20. Понедельникова Н.В., Корженкова Г.П., Летягин В.П., Вишневская Я.В. Выбор способа верификации непальпируемых объемных образований молочной железы на дооперационном этапе. Опухоли женской репродуктивной системы. 2011; 1: 41–5. / Ponedel'nikova N.V., Korzhenkova G.P., Letiagin V.P., Vishnevskaia Ia.V. Vybor sposoba verifikatsii nepal'piruemykh ob"emnykh obrazovanii molochnoi zhelezy na dooperatsionnom etape. Opukholi zhenskoi reproduktivnoi sistemy. 2011; 1: 41–5. [in Russian]
21. Понедельникова Н.В., Корженкова Г.П., Летягин В.П. и др. Возможности чрескожных методов биопсии в верификации микрокальцинатов молочной железы на дооперационном этапе. Опухоли женской репродуктивной системы. 2011; 2: 16–21. / Ponedel'nikova N.V., Korzhenkova G.P., Letiagin V.P. i dr. Vozmozhnosti chreskozhnykh metodov biopsii v verifikatsii mikrokal'tsinatov molochnoi zhelezy na dooperatsionnom etape. Opukholi zhenskoi reproduktivnoi sistemy. 2011; 2: 16–21. [in Russian]
22. Радзинский В.Е. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии. Под ред. В.Е.Радзинского. 2-е изд., перераб. и доп. М.: ГОЭТАР-Медиа, 2014. / Radzinskii V.E. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. Pod red. V.E.Radzinskogo. 2-e izd., pererab. i dop. M.: GOETAR-Media, 2014. [in Russian]
23. Рожкова Н.И. и др. Диффузные доброкачественные заболевания молочной железы. Диагностика и лечение: руководство для врачей. Под ред. В.А.Солодкого, Н.И.Рожковой. М.: Спец. изд-во мед. кн., 2012. / Rozhkova N.I. i dr. Diffuznye dobrokachestvennye zabolevaniia molochnoi zhelezy. Diagnostika i lechenie: rukovodstvo dlia vrachei. Pod red. V.A.Solodkogo, N.I.Rozhkovoi. M.: Spets. izd-vo med. kn., 2012. [in Russian]
24. Самушия М.А. Психические расстройства у пациенток со злокачественными опухолями органов женской репродуктивной системы: обзор литературы. Злокачественные опухоли. 2014; 1: 86–95. / Samushiia M.A. Psikhicheskie rasstroistva u patsientok so zlokachestvennymi opukholiami organov zhenskoi reproduktivnoi sistemy: obzor literatury. Zlokachestvennye opukholi. 2014; 1: 86–95. [in Russian]
25. Семиглазов В.Ф., Семиглазов В.В., Дашян Г.А. Рак молочной железы и беременность. Мед. академ. журн. 2009; 3: 66–73. / Semiglazov V.F., Semiglazov V.V., Dashian G.A. Rak molochnoi zhelezy i beremennost'. Med. akadem. zhurn. 2009; 3: 66–73. [in Russian]
26. Снегирев А.А, Григоренко А.А. Особенности акушерско-гинекологического анамнеза женщин с раком молочной железы. Дальневосточный мед. журн. 2012; 3: 48–50. / Snegirev A.A, Grigorenko A.A. Osobennosti akushersko-ginekologicheskogo anamneza zhenshchin s rakom molochnoi zhelezy. Dal'nevostochnyi med. zhurn. 2012; 3: 48–50. [in Russian]
27. Устимов Д.Ю. К вопросу о психогенных факторах в патогенезе дисгормональных очаговых заболеваний молочной железы. Неврол. вестн. 2003; XXXV (Вып. 1–2): 50–1. / Ustimov D.Iu. K voprosu o psikhogennykh faktorakh v patogeneze disgormonal'nykh ochagovykh zabolevanii molochnoi zhelezy. Nevrol. vestn. 2003; XXXV (Vyp. 1–2): 50–1. [in Russian]
28. Харченко В.П. Маммология: национальное руководство. Под ред. В.П.Харченко, Н.И.Рожковой. М.: ГЭОТАР-Медиа, 2009. / Kharchenko V.P. Mammologiia: natsional'noe rukovodstvo. Pod red. V.P.Kharchenko, N.I.Rozhkovoi. M.: GEOTAR-Media, 2009. [in Russian]
29. Шайкина А.С., Рыжавский Б.Я, Беков С.В. и др. Иммуногистохимический анализ рецепторов эстрогенов и прогестерона, пролиферации в эпителиоцитах молочной железы. Дальневосточный мед. журн. 2010; 2: 102–5. / Shaikina A.S., Ryzhavskii B.Ia, Bekov S.V. i dr. Immunogistokhimicheskii analiz retseptorov estrogenov i progesterona, proliferatsii v epiteliotsitakh molochnoi zhelezy. Dal'nevostochnyi med. zhurn. 2010; 2: 102–5. [in Russian]
30. Щепотин И.Б., Зотов А.С., Лебедева О.И. Рак грудной железы и репродуктивная функция женщины: рак грудной железы у беременных и вопросы сохранения фертильности после лечения. Клеточная трансплантология и тканевая инженерия. 2012; 1: 59–63. / Shchepotin I.B., Zotov A.S., Lebedeva O.I. Rak grudnoi zhelezy i reproduktivnaia funktsiia zhenshchiny: rak grudnoi zhelezy u beremennykh i voprosy sokhraneniia fertil'nosti posle lecheniia. Kletochnaia transplantologiia i tkanevaia inzheneriia. 2012; 1: 59–63. [in Russian]
31. Allavena P, Garlanda C, Borrello MG et al. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008; 18 (1): 3–10. doi:10.1016/j.gde.2008.01.003
32. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357 (9255): 539–45.
33. Brinton LA. Breast Cancer Risk After Use of Fertility Drugs: Stimulating New Controversy. JNCI 2012; 104 (Issue 13). http://jnci.oxfordjournals.org/
34. Bure LA, Azoulay L, Benjamin A, Abenhaim HA. Pregnancy-Associated Breast Cancer: A Review for the Obstetrical Care Provider. J Obstet Gynaecol Can 2011; 33 (4): 330–7.
35. Cappuccino H, Bonaccio E. Benign breast disease. Surgery: Principles and Practice, 2014. doi:10.2310/7800.2043
36. Cardoso F et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012; 48: 3355–77.
37. Colditz GA, Bohlke K. Priorities for the Primary Prevention of Breast Cancer. CA: A Cancer Journal for Clinicians 2014; 64 (3): 186–94.
38. Davies MC, Jones AL. Pregnancy and Breast Cancer. RCOG. Green-top Guideline No. 12, 2011.
39. Del Prete A, Allavena P, Santoro G et al. Molecular pathways in cancer-related inflammation. Biochemia Medica 2011; 21 (3): 264–75. http://dx.doi.org/10.11613/BM.2011.036
40. El-Mowafi D. Management of Breast cancer during pregnancy. Progress in Obstetrics and Gynecology 16. John Studd (ed.), London UK, 2005.
41. Fei C, DeRoo LA, Sandler DP, Weinberg CR. Fertility Drugs and Young-Onset Breast Cancer: Results From the Two Sister Study. J Natl Cancer Inst 2012; 104: 1021–7.
42. Graham A. Colditz. Priorities for the Primary Prevention of Breast Cancer CA Cancer J Clin 2014; 64: 186–94
43. Haricharan S et al. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. eLife Sciences 2013; 2: e00996.
44. Henderson C, Harris J. Integration of local and systemic therapies. Breast Diseases. Eds. J.Harris et al. 2nd edit. N.Y.: Lippincott Company, 1991; p. 547–58.
45. Hickey M, Peate M, Saunders CM. Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 2009; 15 (3): 323–39.
46. Jerry et al. Pregnancy offers new insights into mechanisms of breast cancer risk and resistance. Breast Cancer Res 2013; 15: 312. http://breast-cancer-research.com/content/15/5/312
47. Khawaja A, Rao S, Li L, Thompson ChL. Sleep Duration and Breast Cancer Phenotype. J Cancer Epidemiol. 2013; 2013. Article ID 467927. http://dx.doi.org/10.1155/2013/467927http://www.hindawi.com/journals/jce/2013/467927/
48. Kurta et al. Use of fertility drugs and risk of ovarian cancer: results from a US-based case-control study. Cancer Epidemiol Biomarkers Prev 2012; 21 (8): 1282–92. doi: 10.1158/1055-9965.EPI-12-0426/
49. Lanfranchi AE, Fagan P. Breast Cancer and Induced Abortion: A Comprehensive Review of Breast Development and Pathophysiology, theEpidemiologic Literature, and Proposal for Creation of Databanks to Elucidate All Breast Cancer Risk Factors. Issues in Law & Medicine. 2014; 29 (1).
50. Lee and Oh. Effects of interval between age at first pregnancy and age at diagnosis on breast cancer survival according to menopausal status: a register-based study in Korea. BMC Women's Health 2014; 14: 113.
51. Lev M Berstein. Endocrinology of breast cancer: results, tasks and hopes. Expert Rev Endocrinol Metab 2011; 6 (3): 293–7.
52. Litton JK, Theriault RL. Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment The Oncologist 2010; 15: 1238–47.
53. Manshadi Deghan S, Ishiguro L, Sohn K-J et al. Folic Acid Supplementation Promotes Mammary Tumor Progression in a Rat Model. PLoS ONE 2014; 9 (1): e84635. doi:10.1371/journal.pone.0084635
54. Mantovani A, Allavena P, Sica A, Balkwill F. Review Article Cancer-related inflammation. Nature 2008; 454: 436–44. doi: 10.1038/nature07205; Published online 23 July 2008.
55. Melvin L, Craik J, Andrews G. Contraception for Women Aged Over 40 Years Clinical Effectiveness Unit, 2010.
56. Mulcahy N. Lack of sleep linked to Breast Cancer Aggresiveness 2012. http://www.medscape.com/viewarticle/770515
57. Neetu G, Pathmanathan R, Wengb NK. Diabetic Mastopathy: A Case Report and Literature Review. Case Rep Oncol 2010; 3: 245–51.
58. Ningqi Hou et al. Hormone Replacement Therapy and Breast Cancer: Heterogeneous Risks by Race, Weight, and Breast Density JNCI J Natl Cancer Inst 2013; 105 (18): 1365–72. doi: 10.1093/jnci/djt207
59. Pomeranz M. Use of fertility drugs and risk of breast cancer. Harefuah 2013; 152 (10): 598–9, 623.
60. Riskin-Mashiah S. Infertility, fertility treatment and breast cancer risk. Harefuah 2013; 152 (10): 600–4, 623.
61. Russo Lo G, Spinelli GP, Tomao S et al. Breast cancer risk after exposure to fertility drugs. Expert Rev Anticancer Ther 2013; 13 (2): 149–57. doi: 10.1586/era.12.181
62. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19: 3306–11.
63. Thompson Ch.L. Association of sleep duration and breast cancer OncotypeDX reccurence score. Breast cancer research and treatment 2012; 134 (Issue 3): 1291–5.
64. Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA et al. Oral contraceptives, hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older. Acta Oncologica 2014; 53: 752–8.
65. Thun MJ, Henley SJ, Gansler T. Inflammation and cancer: an epidemiological perspective. Novartis Found Symp 2004; 256: 6–21 (discussion 22–8, 49–52, 266–9).
66. Tomao et al. Fertility drugs, reproductive strategies and ovarian cancer risk. J Ovarian Res 2014, 7: 51.
67. http://mediexpo.ru/fileadmin/user_upload/content/program/program_md14.pdf
68. Voss S, Quail D, Dawson A et al. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002; 109 (8): 874–85. PMID: 12197366. http://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.2002.01510.x/pdf
69. Kaskiw MJ, Tassotto ML, Mok M et al. Structural analogues of diosgenyl saponins: synthesis and anticancer activity. Bioorg Med Chem 2009; 17 (22): 7670–9. http://www.sciencedirect.com/science/article/pii/S0968089609008980
70. Chung JG. Effects of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) on the acetylation of 2-aminofluorene and DNA-2-aminofluorene adducts in the rat. Toxicol Sci 1999; 51: 202–210. http://toxsci.oxfordjournals.org/content/51/2/202.full.pdf
________________________________________________
1. Aseev A.V., Vasiutkov V.Ia., Murashova Z.M. Opyt izucheniia kachestva zhizni bol'nykh rakom molochnoi zhelezy (v usloviiakh oblastnogo onkologicheskogo dispansera). Mammologiia. 1995; 3: 40–5. [in Russian]
2. Ashrafian L.A. Sporadicheskii rak iaichnikov: veroiatnaia model' patogeneza. Zhurn. akusherstva i zhenskikh boleznei. 2012; LXI (Vyp. 4): 3–10. [in Russian]
3. Ashrafian L.A., Kiselev V.I. Opukholi reproduktivnykh organov (etiologiia i patogenez). M.: Dimitreid Grafik Grupp, 2007. [in Russian]
4. Bukharin D.G, Slonimskaia E.M., Velichko S.A. i dr. Osobennosti mammograficheskoi vizualizatsii «malykh» form raka molochnoi zhelezy, razvivshegosia na fone fibrozno-kistoznoi bolezni. Vopr. onkologii. 2011; 57 (5): 664–7. [in Russian]
5. Volochaeva M.V., Podushkina E.S., Shmakov R.G., Shetikova O.V. Vedenie beremennosti u zhenshchin s onkologicheskimi zabolevaniiami (10-letnii opyt). Akusherstvo i ginekologiia. 2012; 6: 92–8. [in Russian]
6. Volochaeva M.V., Shmakov R.G., Zubkov V.V. Zdorov'e detei, rozhdennykh zhenshchinami s rakom molochnoi zhelezy, sviazannym s beremennost'iu. Akusherstvo i ginekologiia. 2014; 7: 33–7. [in Russian]
7. Golovko T.S., Skliar S.Iu., Krakhmaleva A.S. i dr. Osobennosti luchevoi diagnostiki redkikh zabolevanii grudnoi zhelezy opukholevoi prirody. Klin. onkologiia. 2011; 3 (3): 86–91. [in Russian]
8. Zakharova T. Mastopatiia v praktike vracha pervichnogo zvena. Med. gazeta. 2014; 13: 8–9. [in Russian]
9. Ivanova O.A. i dr. Rak molochnoi zhelezy i beremennost': osobennosti diagnostiki i lecheniia. Zlokachestvennye opukholi. 2014; 1: 14–8. [in Russian]
10. Kiselev V.I., Smetnik V.P, Suturina L.V. i dr. Indolkarbinol (Indinol Forto) – metod mul'titargetnoi terapii pri tsiklicheskoi mastodinii. Akusherstvo i ginekologiia. 2013; 7. [in Russian]
11. Kit O.I., Frantsiiants E.M., Bandovkina V.A. i dr. Uroven' polovykh gormonov i prolaktina v tkani zlokachestvennykh opukholei molochnoi zhelezy u bol'nykh raznogo vozrasta. Fundamental'nye issledovaniia. 2013; 7: 560–4. [in Russian]
12. Korzhenkova G.P. Sovershenstvovanie diagnostiki raka molochnoi zhelezy v usloviiakh massovogo mammograficheskogo obsledovaniia zhenskogo naseleniia. Avtoref. dis. … d-ra med. nauk. Obninsk, 2013. [in Russian]
13. Moiseenko V.M. «Estestvennaia istoriia» rosta raka molochnoi zhelezy. Prakt. onkologiia. 2002; 3 (1): 6–14. [in Russian]
14. Molochnye zhelezy i ginekologicheskie bolezni. Pod red. V.E.Radzinskogo. M., 2010. [in Russian]
15. Natsional'noe rukovodstvo «Akusherstvo». Pod red. E.K.Ailamaziana, V.I.Kulakova, V.E.Radzinskogo, G.M.Savel'evoi, 2009. [in Russian]
16. Nechushkin M.I., Kampova-Polevaia E.B., Parokonnaia A.A., Liubchenko L.N. Beremennost' u zhenshchin, perenesshikh rak molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2009; 1: 67–71. [in Russian]
17. Osnovnye pokazateli deiatel'nosti akushersko-ginekologicheskoi sluzhby v 2012 godu. Spravochnye materialy (pod red. E.N.Baibarinoi). M., 2013. [in Russian]
18. Parokonnaia A.A. Rak molochnoi zhelezy i beremennost'. Sovremennoe sostoianie problemy. Prakt. onkologiia. 2009; 10 (4): 179–83. [in Russian]
19. Parokonnaia A.A. Rak molochnoi zhelezy i beremennost'. Sprav. fel'dshera i akusherki. 2010; 1: 53–6. [in Russian]
20. Ponedel'nikova N.V., Korzhenkova G.P., Letiagin V.P., Vishnevskaia Ia.V. Vybor sposoba verifikatsii nepal'piruemykh ob"emnykh obrazovanii molochnoi zhelezy na dooperatsionnom etape. Opukholi zhenskoi reproduktivnoi sistemy. 2011; 1: 41–5. [in Russian]
21. Ponedel'nikova N.V., Korzhenkova G.P., Letiagin V.P. i dr. Vozmozhnosti chreskozhnykh metodov biopsii v verifikatsii mikrokal'tsinatov molochnoi zhelezy na dooperatsionnom etape. Opukholi zhenskoi reproduktivnoi sistemy. 2011; 2: 16–21. [in Russian]
22. Radzinskii V.E. Rukovodstvo po ambulatorno-poliklinicheskoi pomoshchi v akusherstve i ginekologii. Pod red. V.E.Radzinskogo. 2-e izd., pererab. i dop. M.: GOETAR-Media, 2014. [in Russian]
23. Rozhkova N.I. i dr. Diffuznye dobrokachestvennye zabolevaniia molochnoi zhelezy. Diagnostika i lechenie: rukovodstvo dlia vrachei. Pod red. V.A.Solodkogo, N.I.Rozhkovoi. M.: Spets. izd-vo med. kn., 2012. [in Russian]
24. Samushiia M.A. Psikhicheskie rasstroistva u patsientok so zlokachestvennymi opukholiami organov zhenskoi reproduktivnoi sistemy: obzor literatury. Zlokachestvennye opukholi. 2014; 1: 86–95. [in Russian]
25. Semiglazov V.F., Semiglazov V.V., Dashian G.A. Rak molochnoi zhelezy i beremennost'. Med. akadem. zhurn. 2009; 3: 66–73. [in Russian]
26. Snegirev A.A, Grigorenko A.A. Osobennosti akushersko-ginekologicheskogo anamneza zhenshchin s rakom molochnoi zhelezy. Dal'nevostochnyi med. zhurn. 2012; 3: 48–50. [in Russian]
27. Ustimov D.Iu. K voprosu o psikhogennykh faktorakh v patogeneze disgormonal'nykh ochagovykh zabolevanii molochnoi zhelezy. Nevrol. vestn. 2003; XXXV (Vyp. 1–2): 50–1. [in Russian]
28. Kharchenko V.P. Mammologiia: natsional'noe rukovodstvo. Pod red. V.P.Kharchenko, N.I.Rozhkovoi. M.: GEOTAR-Media, 2009. [in Russian]
29. Shaikina A.S., Ryzhavskii B.Ia, Bekov S.V. i dr. Immunogistokhimicheskii analiz retseptorov estrogenov i progesterona, proliferatsii v epiteliotsitakh molochnoi zhelezy. Dal'nevostochnyi med. zhurn. 2010; 2: 102–5. [in Russian]
30. Shchepotin I.B., Zotov A.S., Lebedeva O.I. Rak grudnoi zhelezy i reproduktivnaia funktsiia zhenshchiny: rak grudnoi zhelezy u beremennykh i voprosy sokhraneniia fertil'nosti posle lecheniia. Kletochnaia transplantologiia i tkanevaia inzheneriia. 2012; 1: 59–63. [in Russian]
31. Allavena P, Garlanda C, Borrello MG et al. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008; 18 (1): 3–10. doi:10.1016/j.gde.2008.01.003
32. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357 (9255): 539–45.
33. Brinton LA. Breast Cancer Risk After Use of Fertility Drugs: Stimulating New Controversy. JNCI 2012; 104 (Issue 13). http://jnci.oxfordjournals.org/
34. Bure LA, Azoulay L, Benjamin A, Abenhaim HA. Pregnancy-Associated Breast Cancer: A Review for the Obstetrical Care Provider. J Obstet Gynaecol Can 2011; 33 (4): 330–7.
35. Cappuccino H, Bonaccio E. Benign breast disease. Surgery: Principles and Practice, 2014. doi:10.2310/7800.2043
36. Cardoso F et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012; 48: 3355–77.
37. Colditz GA, Bohlke K. Priorities for the Primary Prevention of Breast Cancer. CA: A Cancer Journal for Clinicians 2014; 64 (3): 186–94.
38. Davies MC, Jones AL. Pregnancy and Breast Cancer. RCOG. Green-top Guideline No. 12, 2011.
39. Del Prete A, Allavena P, Santoro G et al. Molecular pathways in cancer-related inflammation. Biochemia Medica 2011; 21 (3): 264–75. http://dx.doi.org/10.11613/BM.2011.036
40. El-Mowafi D. Management of Breast cancer during pregnancy. Progress in Obstetrics and Gynecology 16. John Studd (ed.), London UK, 2005.
41. Fei C, DeRoo LA, Sandler DP, Weinberg CR. Fertility Drugs and Young-Onset Breast Cancer: Results From the Two Sister Study. J Natl Cancer Inst 2012; 104: 1021–7.
42. Graham A. Colditz. Priorities for the Primary Prevention of Breast Cancer CA Cancer J Clin 2014; 64: 186–94
43. Haricharan S et al. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. eLife Sciences 2013; 2: e00996.
44. Henderson C, Harris J. Integration of local and systemic therapies. Breast Diseases. Eds. J.Harris et al. 2nd edit. N.Y.: Lippincott Company, 1991; p. 547–58.
45. Hickey M, Peate M, Saunders CM. Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 2009; 15 (3): 323–39.
46. Jerry et al. Pregnancy offers new insights into mechanisms of breast cancer risk and resistance. Breast Cancer Res 2013; 15: 312. http://breast-cancer-research.com/content/15/5/312
47. Khawaja A, Rao S, Li L, Thompson ChL. Sleep Duration and Breast Cancer Phenotype. J Cancer Epidemiol. 2013; 2013. Article ID 467927. http://dx.doi.org/10.1155/2013/467927http://www.hindawi.com/journals/jce/2013/467927/
48. Kurta et al. Use of fertility drugs and risk of ovarian cancer: results from a US-based case-control study. Cancer Epidemiol Biomarkers Prev 2012; 21 (8): 1282–92. doi: 10.1158/1055-9965.EPI-12-0426/
49. Lanfranchi AE, Fagan P. Breast Cancer and Induced Abortion: A Comprehensive Review of Breast Development and Pathophysiology, theEpidemiologic Literature, and Proposal for Creation of Databanks to Elucidate All Breast Cancer Risk Factors. Issues in Law & Medicine. 2014; 29 (1).
50. Lee and Oh. Effects of interval between age at first pregnancy and age at diagnosis on breast cancer survival according to menopausal status: a register-based study in Korea. BMC Women's Health 2014; 14: 113.
51. Lev M Berstein. Endocrinology of breast cancer: results, tasks and hopes. Expert Rev Endocrinol Metab 2011; 6 (3): 293–7.
52. Litton JK, Theriault RL. Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment The Oncologist 2010; 15: 1238–47.
53. Manshadi Deghan S, Ishiguro L, Sohn K-J et al. Folic Acid Supplementation Promotes Mammary Tumor Progression in a Rat Model. PLoS ONE 2014; 9 (1): e84635. doi:10.1371/journal.pone.0084635
54. Mantovani A, Allavena P, Sica A, Balkwill F. Review Article Cancer-related inflammation. Nature 2008; 454: 436–44. doi: 10.1038/nature07205; Published online 23 July 2008.
55. Melvin L, Craik J, Andrews G. Contraception for Women Aged Over 40 Years Clinical Effectiveness Unit, 2010.
56. Mulcahy N. Lack of sleep linked to Breast Cancer Aggresiveness 2012. http://www.medscape.com/viewarticle/770515
57. Neetu G, Pathmanathan R, Wengb NK. Diabetic Mastopathy: A Case Report and Literature Review. Case Rep Oncol 2010; 3: 245–51.
58. Ningqi Hou et al. Hormone Replacement Therapy and Breast Cancer: Heterogeneous Risks by Race, Weight, and Breast Density JNCI J Natl Cancer Inst 2013; 105 (18): 1365–72. doi: 10.1093/jnci/djt207
59. Pomeranz M. Use of fertility drugs and risk of breast cancer. Harefuah 2013; 152 (10): 598–9, 623.
60. Riskin-Mashiah S. Infertility, fertility treatment and breast cancer risk. Harefuah 2013; 152 (10): 600–4, 623.
61. Russo Lo G, Spinelli GP, Tomao S et al. Breast cancer risk after exposure to fertility drugs. Expert Rev Anticancer Ther 2013; 13 (2): 149–57. doi: 10.1586/era.12.181
62. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19: 3306–11.
63. Thompson Ch.L. Association of sleep duration and breast cancer OncotypeDX reccurence score. Breast cancer research and treatment 2012; 134 (Issue 3): 1291–5.
64. Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA et al. Oral contraceptives, hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older. Acta Oncologica 2014; 53: 752–8.
65. Thun MJ, Henley SJ, Gansler T. Inflammation and cancer: an epidemiological perspective. Novartis Found Symp 2004; 256: 6–21 (discussion 22–8, 49–52, 266–9).
66. Tomao et al. Fertility drugs, reproductive strategies and ovarian cancer risk. J Ovarian Res 2014, 7: 51.
67. http://mediexpo.ru/fileadmin/user_upload/content/program/program_md14.pdf
68. Voss S, Quail D, Dawson A et al. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002; 109 (8): 874–85. PMID: 12197366. http://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.2002.01510.x/pdf
69. Kaskiw MJ, Tassotto ML, Mok M et al. Structural analogues of diosgenyl saponins: synthesis and anticancer activity. Bioorg Med Chem 2009; 17 (22): 7670–9. http://www.sciencedirect.com/science/article/pii/S0968089609008980
70. Chung JG. Effects of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) on the acetylation of 2-aminofluorene and DNA-2-aminofluorene adducts in the rat. Toxicol Sci 1999; 51: 202–210. http://toxsci.oxfordjournals.org/content/51/2/202.full.pdf
Авторы
В.А.Новикова*1, Г.А.Пенжоян1,2
1. ГБОУ ВПО Кубанский государственный медицинский университет Минздрава России. 350063, Россия, Краснодар, ул. Седина, д. 4;
2. ГБУЗ Краевая клиническая больница №2 Минздрава Краснодарского края.
350012, Россия, Краснодар, ул. Красных партизан, д. 6/2
*vladislavan@mail.ru
________________________________________________
V.A.Novikova*1, G.A.Penzhoyan1,2
1. Kuban State Medical University of the Ministry of Health of the Russian Federation. 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4;
2. Regional Clinical Hospital №2 of the Ministry of Health of the Krasnodar Region. 350012, Russian Federation, Krasnodar, ul. Krasnykh partizan, d. 6/2
*vladislavan@mail.ru